J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021
Executive Summary
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.
You may also be interested in...
Real-World Data, AI Play Key Roles In COVID-19 Vaccine Programs
RWD has helped with development of multiple SARS-CoV-2 vaccines already and could be a useful tool for the future, as panelists discussed at the AI Cures conference.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
J&J Bounces Back In Q3, Led By Interventional Devices
Johnson & Johnson’s worldwide medical device revenues grew about 50% sequentially in the third quarter to $6.2bn.